Genedx Holdings Corp Stock Analysis
| WGS Stock | 79.43 1.09 1.35% |
GeneDx Holdings Corp is overvalued with Real Value of 42.67 and Target Price of 9.88. The main objective of GeneDx Holdings stock analysis is to determine its intrinsic value, which is an estimate of what GeneDx Holdings Corp is worth, separate from its market price. There are two main types of GeneDx Holdings' stock analysis: fundamental analysis and technical analysis.
The GeneDx Holdings stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. GeneDx Holdings is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. GeneDx Stock trading window is adjusted to America/New York timezone.
GeneDx |
GeneDx Stock Analysis Notes
About 18.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 3.09. GeneDx Holdings Corp had not issued any dividends in recent years. The entity had 1:33 split on the 4th of May 2023. For more information please call Katherine Stueland at 888 729 1206 or visit https://www.genedx.com.GeneDx Holdings Quarterly Total Revenue |
|
GeneDx Holdings Corp Investment Alerts
| GeneDx Holdings Corp is way too risky over 90 days horizon | |
| GeneDx Holdings Corp appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 202.57 M. Reported Net Loss for the year was (175.77 M) with loss before taxes, overhead, and interest of (26.75 M). | |
| GeneDx Holdings generates negative cash flow from operations | |
| GeneDx Holdings Corp has a frail financial position based on the latest SEC disclosures | |
| About 70.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: GeneDx Holdings Corp Trading Down 3.45 percent on Nov 27 |
GeneDx Holdings Corp Upcoming and Recent Events
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
GeneDx Largest EPS Surprises
Earnings surprises can significantly impact GeneDx Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-15 | 2022-06-30 | -0.21 | -0.25 | -0.04 | 19 | ||
2023-03-14 | 2022-12-31 | -0.16 | -0.25 | -0.09 | 56 | ||
2022-03-14 | 2021-12-31 | -0.26 | -0.17 | 0.09 | 34 |
GeneDx Holdings Environmental, Social, and Governance (ESG) Scores
GeneDx Holdings' ESG score is a quantitative measure that evaluates GeneDx Holdings' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of GeneDx Holdings' operations that may have significant financial implications and affect GeneDx Holdings' stock price as well as guide investors towards more socially responsible investments.
GeneDx Holdings Thematic Classifications
In addition to having GeneDx Holdings stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Health ManagementHealthcare providers, hospitals | |
 | HealthcareUSA Equities from Healthcare industry as classified by Fama & French |
GeneDx Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 2.18 B.GeneDx Profitablity
The company has Net Profit Margin of (0.31) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.1) %, which entails that for every $100 of revenue, it lost $0.1.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.77) | (0.81) |
Management Efficiency
GeneDx Holdings Corp has Return on Asset of (0.0827) % which means that on every $100 spent on assets, it lost $0.0827. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.364) %, meaning that it generated no profit with money invested by stockholders. GeneDx Holdings' management efficiency ratios could be used to measure how well GeneDx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. At this time, GeneDx Holdings' Net Tangible Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 13.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 197.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.38 | 9.85 | |
| Tangible Book Value Per Share | 2.28 | 2.39 | |
| Enterprise Value Over EBITDA | (0.64) | (0.61) | |
| Price Book Value Ratio | 0.29 | 0.52 | |
| Enterprise Value Multiple | (0.64) | (0.61) | |
| Price Fair Value | 0.29 | 0.52 | |
| Enterprise Value | 86.9 M | 91.3 M |
At GeneDx Holdings Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Operating Margin (0.10) | Profit Margin (0.31) | Beta 2.18 | Return On Assets (0.08) | Return On Equity (0.36) |
Technical Drivers
As of the 29th of November, GeneDx Holdings retains the Risk Adjusted Performance of 0.1592, market risk adjusted performance of 2.09, and Downside Deviation of 3.82. Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of GeneDx Holdings Corp, as well as the relationship between them. Please check out GeneDx Holdings Corp variance and potential upside to decide if GeneDx Holdings is priced fairly, providing market reflects its last-minute price of 79.43 per share. Given that GeneDx Holdings Corp has jensen alpha of 1.37, we strongly advise you to confirm GeneDx Holdings Corp's regular market performance to make sure the company can sustain itself at a future point.GeneDx Holdings Corp Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. GeneDx Holdings middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for GeneDx Holdings Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
GeneDx Holdings Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GeneDx Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on GeneDx Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GeneDx Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GeneDx Holdings Predictive Daily Indicators
GeneDx Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GeneDx Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GeneDx Holdings Corporate Filings
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 21st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 20th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 4th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
F4 | 31st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
GeneDx Holdings Forecast Models
GeneDx Holdings' time-series forecasting models are one of many GeneDx Holdings' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GeneDx Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About GeneDx Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how GeneDx Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GeneDx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as GeneDx Holdings. By using and applying GeneDx Stock analysis, traders can create a robust methodology for identifying GeneDx entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.87) | (0.92) | |
| Operating Profit Margin | (0.81) | (0.85) | |
| Net Loss | (0.87) | (0.91) | |
| Gross Profit Margin | 0.30 | 0.31 |
Current GeneDx Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GeneDx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. GeneDx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 9.88 | Buy | 6 | Odds |
Most GeneDx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand GeneDx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of GeneDx Holdings Corp, talking to its executives and customers, or listening to GeneDx conference calls.
GeneDx Stock Analysis Indicators
GeneDx Holdings Corp stock analysis indicators help investors evaluate how GeneDx Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading GeneDx Holdings shares will generate the highest return on investment. By understating and applying GeneDx Holdings stock analysis, traders can identify GeneDx Holdings position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 137.4 M | |
| Total Stockholder Equity | 228 M | |
| Capital Lease Obligations | 66.6 M | |
| Property Plant And Equipment Net | 59.4 M | |
| Cash And Short Term Investments | 130.1 M | |
| Net Invested Capital | 281.2 M | |
| Cash | 99.7 M | |
| 50 Day M A | 61.3316 | |
| Net Interest Income | 1.1 M | |
| Total Current Liabilities | 58.8 M | |
| Investments | -41.7 M | |
| Stock Based Compensation | -326 K | |
| Long Term Debt | 52.7 M | |
| Common Stock Shares Outstanding | 24.3 M | |
| Tax Provision | -926 K | |
| Free Cash Flow | -185.9 M | |
| Other Current Assets | 10.6 M | |
| Accounts Payable | 10.2 M | |
| Net Debt | 20.1 M | |
| Depreciation | 35.8 M | |
| Other Operating Expenses | 366.2 M | |
| Non Current Assets Total | 291.3 M | |
| Liabilities And Stockholders Equity | 473.7 M | |
| Non Currrent Assets Other | 58.3 M |
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.